1 / 39

Drug Treatment Disparities Among African Americans Living with HIV/AIDS

Drug Treatment Disparities Among African Americans Living with HIV/AIDS. Carleen H. Stoskopf, Sc.D. William Pearson, Ph.D. Jong Deuk Baek, Ph.D. Yunho Jeon, M.S. Background.

dreama
Download Presentation

Drug Treatment Disparities Among African Americans Living with HIV/AIDS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Drug Treatment Disparities Among African Americans Living with HIV/AIDS Carleen H. Stoskopf, Sc.D. William Pearson, Ph.D. Jong Deuk Baek, Ph.D. Yunho Jeon, M.S.

  2. Background • Many studies have identified disparities in health status, health care access, and health care utilization by race/ethnicity. • In the late 1990s, clinical trials found the high efficacy of Highly Active Antiretroviral Therapy (HAART). • Researchers found that African Americans were significantly less likely to use newer antiretroviral regimens (e.g., protease inhibitors and NNRTIs).

  3. Background continued • Several studies found that racial/ethnic minorities were less likely to use drugs for opportunistic diseases than whites (e.g., PCP and TB/MAC prophylaxis). • This study explores changes in use of HAART and drugs for opportunistic diseases and to determine factors that influence the use of HAART by race/ethnicity.

  4. HIV Cost and Services Utilization Study (HCSUS) data • Nationally representative sample • Adults in care for HIV • Multi-stage design (n = 4,042) • Geographical • Medical provider • Patients

  5. HCSUS data • Panel study • Baseline: January ’96 - March ’97 • N = 2,864 (71%) • First follow-up: December ’96 - July ’97 • N = 2,466 (61%) • Second follow-up: August ’97 - January ’98 • N = 2,267 (56%))

  6. Independent Variables • Age • Gender • Race • Mode of HIV exposure • Household composition • Employment status • Educational attainment

  7. Independent Variables • Insurance status • Household income • Lowest reported CD4 cell count

  8. Dependent Variables • HAART: Coded as a positive response if the person indicated taking HAART in the past six months • Combinations of NRTI plus certain PI or NNRTI • 99% of the sample met the published eligibility criteria in 1996 for HAART • CD4 < 500 cells/μl OR HIV RNA > 10,000 copies/ml OR symptomatic HIV or AIDS • Handout 1

  9. Dependent VariablesOpportunistic Infections Rx • Cytomegalovirus (CMV) • Common herpes virus causing retinitis and colitis • Pneumocystic Carinii Pneumonia (PCP) • Infection of the lungs caused by Pneumocystis carinii • Tuberculosis (TB) • Bacterial infection, Mycobacterium tuberculosis

  10. Dependent VariablesOpportunistic Infections Rx • Mycobacterium Avium Complex • Bacterial infections, Mycobacterium avium, Mycobacterium intracellulare • Fungal Infections • Herpes Simplex Viruses • HSV-1, HSV-2 • Immune System Boosters

  11. Analysis • Description of Sample • National estimates • Bivariate analysis • Multivariate analysis (Odds Ratio)

  12. Results of Analyses

  13. Sample Characteristics of Respondents • Distribution of the sample respondents is consistent for all three surveys • All sample frequencies decrease across surveys except for Medicare recipients and some CD4 counts. • Table 1

  14. Sample Characteristics of Respondents

  15. Sample Characteristics of Respondents

  16. Sample Characteristics of Respondents

  17. Sample Characteristics of Respondents

  18. Sample Characteristics of Respondents

  19. Sample Characteristics of Respondents

  20. Sample Characteristics of Respondents

  21. Sample Characteristics of Respondents

  22. Sample Characteristics of Respondents

  23. Sample Characteristics of Respondents

  24. HAART Use in the Three Consecutive Surveys • Test of Independence (Chi square) • Proportions of HAART use were dramatically increased (sample frequencies and estimated population weighted percentages) across all three surveys. • All independent variables are statistically significant except age in the two follow-ups. • Table 2

  25. Weighted Population Estimate (%) of HAART Use by Race/Ethnicity • African Americans are less likely to use HAART than other racial/ethnic groups.

  26. Weighted Population Estimate (%) of HAART Use by Gender • Females are less likely to use HAART than males, but the gap closes over the three surveys.

  27. Weighted Population Estimate (%) of HAART Use by Employment Status • Those who are employed full time, or those who are disabled, are more likely to use HAART.

  28. Weighted Population Estimate (%) of HAART Use by Education • Those who are more highly educated are more likely to use HAART.

  29. Weighted Population Estimate (%) of HAART Use by Insurance Status • Those persons who have private insurance are more likely to use HAART.

  30. Weighted Population Estimate (%) of HAART Use by Income • Those with higher incomes are more likely to use HAART.

  31. Weighted Population Estimate (%) of HAART Use by CD 4 Cell Count • Those with lower CD4 counts are more likely to use HAART.

  32. Rx for Opportunistic Diseases in the Three Consecutive Surveys • Test of Independence (Chi square) for Race/Ethnicity • African Americans are the least likely group to use drugs for opportunistic diseases. • This finding is true across all three surveys, except for TB treatment in the second follow-up survey. • Table 3

  33. Multivariate Logistic RegressionUse of HAART • The multivariate logistic Regression allows for controlling the influence of the various independent variables. • Race (being African American) is consistently statistically significant across all three surveys. When compared to Whites, AA are significantly less likely to have used HAART in the last six months. • Odds ratios are 0.32, 0.54, and 0.70, respectively • Table 4

  34. Multivariate Logistic RegressionUse of HAART • Other significant findings include: • Men having sex with men are more likely to use HAART at the second follow-up • Those who are unemployed or not working are less likely to use HAART at the baseline survey, those not working are still less likely to use HAART at the first follow-up.

  35. Multivariate Logistic RegressionUse of HAART • As compared to the uninsured, those with Medicaid, private insurance, private HMO, or Medicare were significantly more likely to be receiving HAART at the baseline survey. • At the second survey (first follow-up) only those with private insurance had a statistically significant advantage • As expected, those with the lowest CD4 counts were significantly more likely to receive HAART therapy.

  36. Multivariate Logistic Regression Rx for Opportunistic Diseases Baseline Survey African Americans were significantly less likely than Whites to receive drug treatment for these disease categories: Cytomegalovirus Pneumocystis Tuberculosis Fungal Infections Herpes Immune System Booster Table 5 - 10

  37. Multivariate Logistic Regression Rx for Opportunistic Diseases • Second survey (first follow-up) • At the second survey, African Americans were significantly less likely to receive drug treatment for all disease except pneumocystis. These include: • Cytomegalovirus Tuberculoses • Fungal Infections Herpes

  38. Multivariate Logistic Regression Rx for Opportunistic Diseases • Third survey (second follow-up) • By the third survey, African Americans were still significantly less likely than Whites to receive drug treatment for: Cytomegalovirus Tuberculosis Fungal Infections

  39. Conclusions • African Americans were consistently less likely to receive appropriate treatment for HIV/AIDS and other infections associated with this disease as HAART was introduced. • Over time, the racial disparities in HAART use decrease, but statistical differences remain between African Americans and Whites.

More Related